Advances in sodium-glucose transporter protein 2 inhibitors and tumors
Tumor is a major challenge to global health and has received extensive attention worldwide due to its high degree of malignancy and poor prognosis. Although the clinical application of targeted therapy and immunotherapy has improved the status quo of tumor treatment, the development of new therapeut...
Saved in:
Main Authors: | Jiaqi Wang, Wenyong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1522059/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01) -
Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01) -
Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01) -
Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01) -
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
by: Xiaoyan Liang, et al.
Published: (2025-01-01)